<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Iron for the treatment of restless legs syndrome - Trotti, LM - 2019 | Cochrane Library</title> <meta content="Iron for the treatment of restless legs syndrome - Trotti, LM - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007834.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Iron for the treatment of restless legs syndrome - Trotti, LM - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007834.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007834.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Iron for the treatment of restless legs syndrome" name="citation_title"/> <meta content="Lynn M Trotti" name="citation_author"/> <meta content="Emory University School of Medicine" name="citation_author_institution"/> <meta content="lbecke2@emory.edu" name="citation_author_email"/> <meta content="Lorne A Becker" name="citation_author"/> <meta content="SUNY Upstate Medical University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD007834.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/01/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007834.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007834.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007834.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Dopamine Agonists [adverse effects, therapeutic use]; Ferric Compounds [adverse effects, therapeutic use]; Ferric Oxide, Saccharated [adverse effects, therapeutic use]; Ferrous Compounds [adverse effects, therapeutic use]; Iron [adverse effects, *therapeutic use]; Maltose [adverse effects, analogs &amp; derivatives, therapeutic use]; Patient Dropouts [statistics &amp; numerical data]; Pramipexole [adverse effects, therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic; Restless Legs Syndrome [*therapy]; Trace Elements [adverse effects, *therapeutic use]; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007834.pub3&amp;doi=10.1002/14651858.CD007834.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="jiwTpTuf";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007834\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007834\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","ru","ja","pl","ms","hr","fa","zh_HANT"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007834.pub3",title:"Iron for the treatment of restless legs syndrome",firstPublishedDate:"Jan 4, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Movement Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007834.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007834.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007834.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007834.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007834.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007834.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007834.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007834.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007834.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007834.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10672 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007834.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/full#CD007834-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/full#CD007834-sec-0084"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/full#CD007834-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/full#CD007834-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/full#CD007834-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/full#CD007834-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/full#CD007834-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/full#CD007834-sec-0078"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/appendices#CD007834-sec-0089"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/table_n/CD007834StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/table_n/CD007834StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Iron for the treatment of restless legs syndrome</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/information#CD007834-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Lynn M Trotti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007834.pub3/information#CD007834-cr-0003">Lorne A Becker</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/information/en#CD007834-sec-0093">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 January 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007834.pub3">https://doi.org/10.1002/14651858.CD007834.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007834-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007834-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007834-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007834-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007834-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007834-abs-0001" lang="en"> <section id="CD007834-sec-0001"> <h3 class="title" id="CD007834-sec-0001">Background</h3> <p>Restless legs syndrome (RLS) is a common neurologic disorder that is associated with peripheral iron deficiency in a subgroup of patients. It is unclear whether iron therapy is effective treatment for RLS. </p> </section> <section id="CD007834-sec-0002"> <h3 class="title" id="CD007834-sec-0002">Objectives</h3> <p>To evaluate the efficacy and safety of oral or parenteral iron for the treatment of restless legs syndrome (RLS) when compared with placebo or other therapies. </p> </section> <section id="CD007834-sec-0003"> <h3 class="title" id="CD007834-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycNFO, and CINAHL for the time period January 1995 to September 2017. We searched reference lists for additional published studies. We searched Clinicaltrials.gov and other clinical trial registries (September 2017) for ongoing or unpublished studies. </p> </section> <section id="CD007834-sec-0004"> <h3 class="title" id="CD007834-sec-0004">Selection criteria</h3> <p>Controlled trials comparing any formulation of iron with placebo, other medications, or no treatment, in adults diagnosed with RLS according to expert clinical interview or explicit diagnostic criteria. </p> </section> <section id="CD007834-sec-0005"> <h3 class="title" id="CD007834-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed trial quality, with discussion to reach consensus in the case of any disagreement. The primary outcome considered in this review was restlessness or unpleasant sensations, as experienced subjectively by the patient. We combined treatment/control differences in the outcomes across studies using random‐effects meta‐analyses. We analysed continuous data using mean differences (MDs) where possible and performed standardised mean difference (SMD) analyses when different measurements were used across studies. We calculated risk ratios (RRs) for dichotomous data using the Mantel‐Haenszel method and 95% confidence intervals (CIs). We analysed study heterogeneity using the I<sup>2</sup> statistic. We used standard methodological procedures expected by Cochrane. We performed GRADE analysis using GRADEpro. </p> </section> <section id="CD007834-sec-0006"> <h3 class="title" id="CD007834-sec-0006">Main results</h3> <p>We identified and included 10 studies (428 total participants, followed for 2‐16 weeks) in this review. Our primary outcome was restlessness or uncomfortable leg sensations, which was quantified using the International Restless Legs Scale (IRLS) (range, 0 to 40) in eight trials and a different RLS symptom scale in a ninth trial. Nine studies compared iron to placebo and one study compared iron to a dopamine agonist (pramipexole). The possibility for bias among the trials was variable. Three studies had a single element with high risk of bias, which was lack of blinding in two and incomplete outcome data in one. All studies had at least one feature resulting in unclear risk of bias. </p> <p>Combining data from the seven trials using the IRLS to compare iron and placebo, use of iron resulted in greater improvement in IRLS scores (MD ‐3.78, 95% CI ‐6.25 to ‐1.31; I<sup>2</sup>= 66%, 7 studies, 345 participants) measured 2 to 12 weeks after treatment. Including an eighth study, which measured restlessness using a different scale, use of iron remained beneficial compared to placebo (SMD ‐0.74, 95% CI ‐1.26 to ‐0.23; I<sup>2</sup> = 80%, 8 studies, 370 participants). The GRADE assessment of certainty for this outcome was moderate. </p> <p>The single study comparing iron to a dopamine agonist (pramipexole) found a similar reduction in RLS severity in the two groups (MD ‐0.40, 95% CI ‐5.93 to 5.13, 30 participants). </p> <p>Assessment of secondary outcomes was limited by small numbers of trials assessing each outcome. Iron did not improve quality of life as a dichotomous measure (RR 2.01, 95% CI 0.54 to 7.45; I<sup>2</sup>=54%, 2 studies, 39 participants), but did improve quality of life measured on continuous scales (SMD 0.51, 95% CI 0.15 to 0.87; I<sup>2</sup>= 0%, 3 studies, 128 participants), compared to placebo. Subjective sleep quality was no different between iron and placebo groups (SMD 0.19, 95% CI ‐0.18 to 0.56; I<sup>2</sup> = 9%, 3 studies, 128 participants), nor was objective sleep quality, as measured by change in sleep efficiency in a single study (‐35.5 +/‐ 92.0 versus ‐41.4 +/‐ 98.2, 18 participants). Periodic limb movements of sleep were not significantly reduced with iron compared to placebo ( SMD ‐0.19, 95% CI ‐0.70 to 0.32; I<sup>2</sup> = 0%, 2 studies, 60 participants). Iron did not improve sleepiness compared to placebo, as measured on the Epworth Sleepiness Scale (data not provided, 1 study, 60 participants) but did improve the daytime tiredness item of the RLS‐6 compared to placebo (least squares mean difference ‐1.5, 95% CI ‐2.5 to ‐0.6; 1 study, 110 participants). The GRADE rating for secondary outcomes ranged from low to very low. </p> <p>Prespecified subgroup analyses showed more improvement with iron in those trials studying participants on dialysis. The use of low serum ferritin levels as an inclusion criteria and the use or oral versus intravenous iron did not show significant subgroup differences. </p> <p>Iron did not result in significantly more adverse events than placebo (RR 1.48, 95% CI 0.97 to 2.25; I<sup>2</sup>=45%, 6 studies, 298 participants). A single study reported that people treated with iron therapy experienced fewer adverse events than the active comparator pramipexole. </p> </section> <section id="CD007834-sec-0007"> <h3 class="title" id="CD007834-sec-0007">Authors' conclusions</h3> <p>Iron therapy probably improves restlessness and RLS severity in comparison to placebo. Iron therapy may not increase the risk of side effects in comparison to placebo. We are uncertain whether iron therapy improves quality of life in comparison to placebo. Iron therapy may make little or no difference to pramipexole in restlessness and RLS severity, as well as in the risk of adverse events. The effect on secondary outcomes such as quality of life, daytime functioning, and sleep quality, the optimal timing and formulation of administration, and patient characteristics predicting response require additional study. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007834-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007834-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007834-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007834-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007834-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007834-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007834-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007834-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007834-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007834-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007834-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007834-abs-0015">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007834-abs-0004" lang="en"> <h3>Iron for the treatment of restless legs syndrome</h3> <p><b>Background</b> </p> <p>Restless legs syndrome is a common medical condition that causes uncomfortable urges to move the legs. These urges happen in the evening and at night and can keep people from sleeping well. Low blood levels of iron are often seen in people who have restless legs syndrome. Low blood iron levels may be part of the cause of restless legs syndrome. Iron can be taken as a pill or given as an injection into the bloodstream. We performed this review to see if iron treatment reduces the symptoms of restless legs syndrome. </p> <p><b>Study characteristics</b> </p> <p>We included 10 studies of iron. These 10 studies included 428 people with restless legs syndrome. Not all participants had low blood levels of iron. All participants were adults. Most of the studies used injections of iron, while three studies used iron in pill form. Iron treatment was compared to a non‐active treatment (i.e. a placebo) in nine studies. In one study, iron was compared to another restless legs syndrome treatment called a dopamine agonist. The main measure of interest in our review was the severity of restlessness. This was usually measured using a 10‐question survey regarding severity and effects of urges to move the legs, called the International Restless Legs Syndrome Severity Rating Scale (IRLS). This was measured 2‐4 weeks after injections of iron and 12‐14 weeks after iron in pill form. </p> <p>Four trials were funded by the drug manufacturer. Two trials were funded by the USA National Institutes of Health. Two trials were funded by the workplaces of the study investigators. Two studies did not report who funded the study. The four studies funded by drug manufacturers were the largest. The studies funded by drug companies contributed over half of the total number of participants. </p> <p><b>Key results and quality of evidence</b> </p> <p>Overall, the studies showed that iron is better than a placebo for reducing the severity of restless legs syndrome symptoms, although the benefit was low to moderate. This is mostly based on studies using injections of iron, rather than iron pills. Iron was helpful even if blood iron levels were normal at the start of the study. The quality of the evidence was moderate, because not all completed studies have been published, not all important outcomes have been measured, and not enough people have been studied. Side effects were not more common with iron than with placebo. Based on one study, side effects were less common with iron than with another commonly used restless legs syndrome treatment, although the certainty in this result is very low. More studies are needed to allow people with RLS and doctors to make decisions about who should take iron for restless legs syndrome treatment, using what type of iron, and for how long. The evidence is current to September 2017. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007834-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007834-sec-0084">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007834-sec-0139">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007834-sec-0084"></div> <h3 class="title" id="CD007834-sec-0085">Implications for practice</h3> <section id="CD007834-sec-0085"> <p>Iron probably improves restlessness in people with restless legs syndrome (RLS), compared to placebo, based largely on trials of intravenous iron of moderate quality. However, insufficient data are available to directly determine whether iron or dopamine agonists are more effective or better tolerated, and no data address the question of whether iron or alpha‐2‐delta ligands are more effective or better tolerated. Thus, the decision of whether to use iron as first‐line treatment, as combination therapy with a dopamine agonist or alpha‐2‐delta ligand, or only as a second‐line medication after first‐line agents fail, cannot be fully guided by currently available evidence. </p> </section> <h3 class="title" id="CD007834-sec-0086">Implications for research</h3> <section id="CD007834-sec-0086"> <p>Larger, high‐quality studies are needed to evaluate several key questions that are unanswered by available studies, including: 1) confirmation of the benefit of iron, currently based on small studies of relatively few participants, followed for a short period of time; 2) effect of iron therapy on important secondary outcomes in participants with RLS, such as quality of life and sleep quality; 3) effect of oral iron therapy on RLS symptoms; 4) relative efficacy of different formulations of intravenous iron, e.g. ferric carboxymaltose versus iron sucrose; 5) optimal timing of iron administration and monitoring of treatment response; and 6) specific patient characteristics (e.g. baseline iron stores, renal function) that predict response to treatment. Further work is needed to evaluate both the relative efficacy of iron versus standard RLS treatments and the potential benefit of combination therapy using iron and standard treatment. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007834-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007834-sec-0029"></div> <div class="table" id="CD007834-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Iron compared to placebo for the treatment of restless legs syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Iron compared to placebo for the treatment of restless legs syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Patient or population: people with restless legs syndrome</p> <p>Settings: outpatient clinics</p> <p>Intervention: iron</p> <p>Comparison: placebo</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference with iron compared to placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in IRLS severity scale score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>345<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The average reduction in IRLS severity scores in the placebo group ranged from 0.8 points to 12 points </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The reduction in IRLS severity scores was 3.78 points (1.31 to 6.25) lower in the iron group than in the placebo group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in any measure of restlessness</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370<br/> (8 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>The amount of restlessness in the iron group was on average 0.74 SDs (0.23 to 1.26) less than in the placebo group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Quality of life (dichotomous measure)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>39<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>a b c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.01<br/> (0.54 to 7.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>450 per 1000 reported an improvement in quality of life</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>454 more per 1000<br/> (207 fewer to 2903 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in quality of life (continuous measure)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>a b c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>The improvement in quality of life in the iron group was on average 0.51 SDs (0.15 to 0.87) higher than in the placebo group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrew to use other RLS medication or because of inadequate RLS symptom control</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>391<br/> (9 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>a c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.77<br/> (0.41 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 fewer per 1000<br/> (115 fewer to 92 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>298<br/> (6 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.48<br/> (0.97 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 more per 1000<br/> (8 fewer to 325 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Drop out due to adverse event</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>398<br/> (9 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>a c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.91<br/> (0.50 to 7.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 more per 1000<br/> (8 fewer to 98 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>IRLS</b> : International Restless Legs Scale; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> We downgraded one level for publication bias for several reasons: 1) one study completed in 2012 (<a href="./references#CD007834-bbs2-0029" title="NCT00685815 . Intravenous Iron Metabolism in Restless Legs Syndrome. https://clinicaltrials.gov/ct2/show/NCT00685815 (first submitted 5/23/08). ">NCT00685815</a>) for which published results could not be found in the search; 2) generally small sample sizes; and 3) the majority of participants were in trials funded by pharmaceutical companies.<br/> <sup>b</sup>We downgraded one level for the possibility of selective outcome reporting, as this outcome was infrequently reported across studies.<br/> <sup>c</sup>We downgraded one level because the Optimal Information Size (OIS) calculation suggests insufficient power for this outcome. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007834-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007834-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007834-sec-0102">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD007834-sec-0030"></div> <section id="CD007834-sec-0031"> <h3 class="title" id="CD007834-sec-0031">Description of the condition</h3> <p>Restless legs syndrome (RLS, also known as Willis‐Ekbom Disease) is a common neurologic condition consisting of four cardinal features: an urge to move the legs (which is usually but not invariably associated with unpleasant leg sensations); at least transient relief with movement; worsening with rest; and a predilection to occur during the evening and night. These symptoms must not be better accounted for by another disorder that mimics RLS (<a href="./references#CD007834-bbs2-0037" title="AllenRP , PicchiettiDL , Garcia‐BorregueroD , OndoWG , WaltersAS , WinkelmanJW , et al. International Restless Legs Syndrome Study Group. Restless legs syndrome/Willis‐Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria‐history, rationale, description, and significance. Sleep Medicine2014;15(8):860‐73. ">Allen 2014</a>). The diagnosis is one of clinical judgment, with no definitive confirmatory testing presently available. However, the presence of periodic limb movements, a response to dopaminergic medications, and a positive family history can all provide supportive evidence for the diagnosis (<a href="./references#CD007834-bbs2-0033" title="AllenRP , PicchiettiD , HeningWA , TrenkwalderC , WaltersAS , MontplaisirJ . Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Medicine2003;4:101‐19. ">Allen 2003</a>). Periodic limb movements are repetitive movements of the limb, most often flexion of the great toe and ankle, that occur with a periodicity between 5 and 90 seconds. Periodic limb movements are seen in 80% to 90% of people with RLS (<a href="./references#CD007834-bbs2-0057" title="MontplaisirJ , BoucherS , PoirierG , LavigneG , LapierreO , LesperanceP . Clinical, polysomnographic, and genetic characteristics of restless legs syndrome. Movement Disorders1997;12:61‐5. ">Montplaisir 1997</a>; <a href="./references#CD007834-bbs2-0066" title="TrottiLM , BliwiseDL , GreerSA , SigurdssonAP , GudmundsdottirGB , WesselT , et al. Correlates of PLMS variability over multiple nights and impact upon RLS diagnosis. Sleep Medicine2009;10(6):668‐71. ">Trotti 2009</a>), but they are not specific to RLS (<a href="./references#CD007834-bbs2-0053" title="HornyakM , FeigeB , RiemannD , VoderholzerU . Periodic leg movements in sleep and periodic limb movement disorder: prevalence, clinical significance and treatment. Sleep Medicine Reviews2006;10(3):169‐77. ">Hornyak 2006</a>). </p> <p>RLS is more common in women than in men (<a href="./references#CD007834-bbs2-0040" title="BergerK , LuedemannJ , TrenkwalderC , JohnU , KesslerC . Sex and the risk of restless legs syndrome in the general population. Archives of Internal Medicine2004;164:196‐202. ">Berger 2004</a>), and the prevalence of RLS increases with age (<a href="./references#CD007834-bbs2-0041" title="BliwiseDL . Periodic leg movements in sleep and restless legs syndrome: Considerations in geriatrics. Sleep Medicine Clinics2006;1:263‐71. ">Bliwise 2006</a>). RLS has a prevalence of 5% to 15% in populations of western European descent but lower prevalence in other investigated populations, such as subsets of Asia (0.1% to 5%) (<a href="./references#CD007834-bbs2-0063" title="StefanssonH , RyeDB , HicksA , PeturssonH , IngasonA , ThorgeirssonTE , et al. A genetic risk factor for periodic limb movements in sleep. New England Journal of Medicine2007;357(7):639‐47. ">Stefansson 2007</a>). RLS has long been suspected to have a genetic basis because of the high proportion of sufferers who have a positive family history. Familial linkage studies have identified numerous potentially causative regions (<a href="./references#CD007834-bbs2-0065" title="TrottiLM , BhadrirajuS , RyeDB . An update on the pathophysiology and genetics of restless legs syndrome. Current Neurology and Neuroscience Reports2008;8:281‐7. ">Trotti 2008</a>). Genome‐wide association studies have found single nucleotide polymorphisms in six different genes that confer increased risk for RLS, periodic limb movements of sleep, or both, including BTBD9, MEIS1, MAP2K5, SKOR1, PTPRD, and TOX3 (<a href="./references#CD007834-bbs2-0061" title="SchormairB , KemlinkD , RoeskeD , EcksteinG , XiongL , LichtnerP , et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nature Genetics2008;40(8):946‐8. ">Schormair 2008</a>; <a href="./references#CD007834-bbs2-0063" title="StefanssonH , RyeDB , HicksA , PeturssonH , IngasonA , ThorgeirssonTE , et al. A genetic risk factor for periodic limb movements in sleep. New England Journal of Medicine2007;357(7):639‐47. ">Stefansson 2007</a>; <a href="./references#CD007834-bbs2-0073" title="WinkelmannJ , SchormairB , LichtnerP , RipkeS , XiongL , JalilzadehS , et al. Genome‐wide association study of restless legs syndrome identifies common variants in three genomic regions. Nature Genetics2007;39(8):1000‐6. ">Winkelmann 2007</a>; <a href="./references#CD007834-bbs2-0074" title="WinkelmannJ , CzamaraD , SchormairB , KnaufF , SchulteEC , TrenkwalderC , et al. Genome‐wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genetic2011;7(7):e1002171. ">Winkelmann 2011</a>). Collectively, the population attributable risk for these variants is approximately 80% (<a href="./references#CD007834-bbs2-0059" title="RyeDB . The molecular genetics of restless legs syndrome. Sleep Medicine Clinics2015;10(3):227‐33. ">Rye 2015</a>). </p> <p>Despite these genetic advances, the pathophysiology of RLS has yet to be fully elaborated. What is known about the functions of the recently implicated genes does not yet explain RLS pathology, although both BTBD9 and MEIS1 are now known to interact with iron and dopamine homeostasis, both implicated in RLS (<a href="./references#CD007834-bbs2-0059" title="RyeDB . The molecular genetics of restless legs syndrome. Sleep Medicine Clinics2015;10(3):227‐33. ">Rye 2015</a>). From a clinical standpoint, a state of dopaminergic dysfunction is suspected to cause RLS because people with RLS frequently improve when given low doses of dopaminergic medications (<a href="./references#CD007834-bbs2-0034" title="AllenR . Dopamine and iron in the pathophysiology of restless legs syndrome. Sleep Medicine2004;5:385‐91. ">Allen 2004</a>). More recently, hypotheses have moved from postulating a state of dopamine deficiency to one of dopamine dysregulation, potentially mediated through deficiencies in central nervous system iron (<a href="./references#CD007834-bbs2-0045" title="EarleyCJ , ConnorJ , Garcia‐BorregueroD , JennerP , WinkelmanJ , ZeePC , et al. Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis‐Ekbom Disease). Sleep Medicine2014;15(11):1288‐301. ">Earley 2014</a>). </p> </section> <section id="CD007834-sec-0032"> <h3 class="title" id="CD007834-sec-0032">Description of the intervention</h3> <p>Iron therapy has been used for people with RLS, both those with and those without documented peripheral iron deficiency. Iron supplementation can be provided orally or intravenously, with several formulations available for each method of delivery. Intravenous iron provides the advantage of replenishing iron stores more quickly than oral therapy, which can take weeks to months, and a lower rate of gastrointestinal side effects (<a href="./references#CD007834-bbs2-0039" title="AvniT , BieberA , GrossmanA , GreenH , LeiboviciL , Gafter‐GviliA . The safety of intravenous iron preparations: systematic review and meta‐analysis. Mayo Clinic Proceedings2015;90(1):12‐23. ">Avni 2015</a>). In meta‐analysis, intravenous iron is associated with severe infusion reactions (with a number needed to treat for an additional harmful outcome of 255; i.e. one severe infusion reaction is expected to happen for every 255 participants receiving intravenous iron compared with placebo). However, the overall risk of serious adverse events is not increased with the use of intravenous iron (<a href="./references#CD007834-bbs2-0039" title="AvniT , BieberA , GrossmanA , GreenH , LeiboviciL , Gafter‐GviliA . The safety of intravenous iron preparations: systematic review and meta‐analysis. Mayo Clinic Proceedings2015;90(1):12‐23. ">Avni 2015</a>). </p> </section> <section id="CD007834-sec-0033"> <h3 class="title" id="CD007834-sec-0033">How the intervention might work</h3> <p>Iron deficiency has been implicated in the pathophysiology of RLS based on the clinical findings that people with iron deficiency anaemia have a high frequency of RLS (32%, with clinically significant disease in 24%; <a href="./references#CD007834-bbs2-0035" title="AllenRP , AuerbachS , BahrainH , AuerbachM , EarleyCJ . The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. American Journal of Hematology2013;88:261‐4. ">Allen 2013</a>), and that severity of iron deficiency correlates with the severity of RLS symptoms (<a href="./references#CD007834-bbs2-0044" title="EarleyCJ , AllenRP , BeardJL , ConnorJR . Insight into the pathophysiology of restless legs syndrome. Journal of Neuroscience Research2000;62:623‐8. ">Earley 2000</a>). Treatment with dopamine agonists is sometimes complicated by a phenomenon known as augmentation, in which symptoms return with earlier time of onset, greater severity, and more extensive bodily involvement (<a href="./references#CD007834-bbs2-0033" title="AllenRP , PicchiettiD , HeningWA , TrenkwalderC , WaltersAS , MontplaisirJ . Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Medicine2003;4:101‐19. ">Allen 2003</a>); this treatment complication appears more likely to occur in those people who have iron deficiency (<a href="./references#CD007834-bbs2-0064" title="TrenkwalderC , HoglB , BenesH , KohnenR . Augmentation in restless legs syndrome is associated with low ferritin. Sleep Medicine2008;9(5):572‐4. ">Trenkwalder 2008</a>). Iron exhibits a circadian pattern similar to RLS symptoms; serum iron nadirs occur between 8 pm and midnight, in line with the peak time of RLS symptom severity (<a href="./references#CD007834-bbs2-0044" title="EarleyCJ , AllenRP , BeardJL , ConnorJR . Insight into the pathophysiology of restless legs syndrome. Journal of Neuroscience Research2000;62:623‐8. ">Earley 2000</a>). Studies of iron in people with RLS have demonstrated low cerebrospinal fluid iron levels (<a href="./references#CD007834-bbs2-0044" title="EarleyCJ , AllenRP , BeardJL , ConnorJR . Insight into the pathophysiology of restless legs syndrome. Journal of Neuroscience Research2000;62:623‐8. ">Earley 2000</a>), low iron concentrations in the substantia nigra on magnetic resonance imaging (<a href="./references#CD007834-bbs2-0034" title="AllenR . Dopamine and iron in the pathophysiology of restless legs syndrome. Sleep Medicine2004;5:385‐91. ">Allen 2004</a>), and decreased substantia nigra iron stores on autopsy specimens (<a href="./references#CD007834-bbs2-0043" title="ConnorJR , BoyerPJ , MenziesSL , DellingerB , AllenRP , OndoWG , et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology2003;61:304‐9. ">Connor 2003</a>). Additionally, iron has known interactions with dopamine, acting as a cofactor for tyrosine hydroxylase, the rate‐limiting enzyme in dopamine production. Iron deficient rodents have been shown to have altered dopamine functioning, with increases in presynaptic dopamine, decreased dopamine transporter functioning and dopamine clearance, and elevated levels of extracellular dopamine in the caudate nucleus and putamen (<a href="./references#CD007834-bbs2-0044" title="EarleyCJ , AllenRP , BeardJL , ConnorJR . Insight into the pathophysiology of restless legs syndrome. Journal of Neuroscience Research2000;62:623‐8. ">Earley 2000</a>; <a href="./references#CD007834-bbs2-0045" title="EarleyCJ , ConnorJ , Garcia‐BorregueroD , JennerP , WinkelmanJ , ZeePC , et al. Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis‐Ekbom Disease). Sleep Medicine2014;15(11):1288‐301. ">Earley 2014</a>; <a href="./references#CD007834-bbs2-0058" title="NelsonC , EriksonK , PiñeroDJ , BeardJL . In vivo dopamine metabolism is altered in iron‐deficient anemic rats. Journal of Nutrition1997;127:2282‐8. ">Nelson 1997</a>). </p> </section> <section id="CD007834-sec-0034"> <h3 class="title" id="CD007834-sec-0034">Why it is important to do this review</h3> <p>Current consensus guidelines put forth by the RLS Foundation's Medical Advisory Board recommend iron replacement therapy for people with a low ferritin level (less than 20 micrograms per litre) and consideration of iron therapy, on a case‐by‐case basis, for those with a ferritin level below 75 micrograms per litre (<a href="./references#CD007834-bbs2-0062" title="SilberMH , BeckerPM , EarleyC , Garcia‐BorregueroD , OndoWG . Willis‐Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clinic Proceedings2013;88(9):977‐86. ">Silber 2013</a>). However, previous meta‐analyses have found insufficient evidence to determine whether iron is beneficial (<a href="./references#CD007834-bbs2-0076" title="TrottiLM , BhadrirajuS , BeckerLA . Iron for restless legs syndrome. Cochrane Database of Systematic Reviews2012, Issue 5. [doi: 10.1002/14651858.CD007834.pub2.] ">Trotti 2012</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007834-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007834-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007834-sec-0107">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007834-sec-0035"></div> <p>To evaluate the efficacy and safety of oral or parenteral iron for the treatment of restless legs syndrome (RLS) when compared with placebo or other therapies. The PICO question formulation was, "In people with RLS, does iron improve RLS‐related symptoms and signs, compared to placebo or other interventions." </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007834-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007834-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007834-sec-0108">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007834-sec-0036"></div> <section id="CD007834-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007834-sec-0038"> <h4 class="title">Types of studies</h4> <p>We searched for all controlled trials investigating the treatment of restless legs syndrome (RLS) with oral or parenteral iron versus placebo, versus another drug, or with a no‐intervention control group. We planned to include controlled trials regardless of whether or not they were randomised or blinded. We planned to include parallel and cross‐over trials, but not the second phase of cross‐over trials because washout periods are not universally used or may not be long enough. Trials that allowed concurrent use of other medications, such as dopamine agonists, anticonvulsants or others were considered suitable for inclusion if they allowed equal access to such medications for participants in the iron and control groups. </p> </section> <section id="CD007834-sec-0039"> <h4 class="title">Types of participants</h4> <p>We sought trials on adult participants (18 years or over) of either sex, in whom RLS was diagnosed according to expert clinical interview or to explicit diagnostic criteria, such as those defined by the International Restless Legs Syndrome Study Group (IRLSSG; <a href="./references#CD007834-bbs2-0033" title="AllenRP , PicchiettiD , HeningWA , TrenkwalderC , WaltersAS , MontplaisirJ . Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Medicine2003;4:101‐19. ">Allen 2003</a>). We planned to include trials on pregnant women or people with renal disease (including those with end‐stage renal disease who are on dialysis) and use these in the investigation of study heterogeneity. </p> </section> <section id="CD007834-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Therapy with any dose or regimen of oral or parenteral iron‐containing compounds compared with placebo, other drugs, or no intervention. </p> </section> <section id="CD007834-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD007834-sec-0042"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome considered in this review was restlessness or unpleasant sensations, as experienced subjectively by the participant. We did not prespecify a rating scale or other measure of restlessness, although the majority of studies employed the International Restless Legs Syndrome Study Group severity scale (IRLS; <a href="./references#CD007834-bbs2-0068" title="WaltersAS , LeBrocqC , DharA , HeningW , RosenR , AllenRP , et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Medicine2003;4(2):121‐32. ">Walters 2003</a>). This 10‐question, 40‐point scale addresses the severity and impact of RLS symptoms, with higher scores indicating more severe symptoms. </p> </section> <section id="CD007834-sec-0043"> <h5 class="title">Secondary outcomes</h5> <section id="CD007834-sec-0044"> <h6 class="title">Efficacy‐related outcomes</h6> <p> <ol id="CD007834-list-0001"> <li> <p>Quality of life measures</p> </li> <li> <p>Patient satisfaction with treatment</p> </li> <li> <p>PLM index (number of periodic limb movements per hour of sleep)</p> </li> <li> <p>Sleep quality (subjective and objective)</p> </li> <li> <p>Daytime functioning</p> </li> <li> <p>Decreased occurrence of augmentation (according to the definition in <a href="./references#CD007834-bbs2-0033" title="AllenRP , PicchiettiD , HeningWA , TrenkwalderC , WaltersAS , MontplaisirJ . Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Medicine2003;4:101‐19. ">Allen 2003</a>) </p> </li> </ol> </p> </section> <section id="CD007834-sec-0045"> <h6 class="title">Safety‐related outcomes</h6> <p> <ol id="CD007834-list-0002"> <li> <p>Adverse events during treatment</p> </li> <li> <p>Discontinuation rate due to adverse events</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD007834-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007834-sec-0047"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases: MEDLINE, Embase, CINAHL, PsychINFO (all for the period January 1995 through to September 2017); and the Cochrane Central Register of Controlled Trials (CENTRAL, in the Cochrane Library, most recently available issue at the time of the search). The lower time period limit was set to 1995 because generally accepted diagnostic criteria did not exist until that date (see <a href="./references#CD007834-bbs2-0067" title="WaltersAS . Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Movement Disorders1995;10(5):634‐42. ">Walters 1995</a>). </p> <p>Our MEDLINE search used the Cochrane Highly Sensitive Search Strategy for identifying randomised trials (2008 revision) along with MESH headings and free‐text searches designed to identify studies of iron administration and of participants with restless legs syndrome with high sensitivity (<a href="./appendices#CD007834-sec-0090">Appendix 1</a>). We adapted the MEDLINE search as necessary for use in the other databases searched. </p> </section> <section id="CD007834-sec-0048"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of included studies for other potentially relevant publications in any language. We contacted the corresponding authors of RCTs and selected members of the International Restless Legs Syndrome Study Group to attempt to find additional published and unpublished trials during the initial search. We searched for unpublished, or ongoing trials, or both, in the following registries: US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>), Australia New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>), CenterWatch Clinical Trials Listing Service (<a href="https://www.centerwatch.com/clinical-trials/listings/" target="_blank">https://www.centerwatch.com/clinical‐trials/listings/</a>), Chinese Clinical Trial Registry <a href="http://www.chictr.org.cn/searchprojen.aspx" target="_blank">(http://www.chictr.org.cn/searchprojen.aspx)</a>, EU Community Research &amp; Development Information Service <a href="https://cordis.europa.eu/search/advanced_en" target="_blank">(https://cordis.europa.eu/search/advanced_en)</a>, EU Clinical Trials Register <a href="https://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">(https://www.clinicaltrialsregister.eu/ctr‐search/search)</a>, International Clinical Trials Registry Platform (WHO, <a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>), Hong Kong Clinical Trials Register <a href="http://www.hkuctr.com/search" target="_blank">(http://www.hkuctr.com/search)</a>, Clinical Trials Registry‐India <a href="http://www.ctri.nic.in/Clinicaltrials/advancesearchmain.php" target="_blank">(http://www.ctri.nic.in/Clinicaltrials/advancesearchmain.php)</a>, South African National Clinical Trial Register <a href="http://www.sanctr.gov.za/SAClinicalTrials/tabid/169/Default.aspx" target="_blank">(http://www.sanctr.gov.za/SAClinicalTrials/tabid/169/Default.aspx)</a>, and the UK Clinical Trials Gateway<a href="https://ukctg.nihr.ac.uk/clinical-trials/search-for-a-clinical-trial/" target="_blank">(https://ukctg.nihr.ac.uk/clinical‐trials/search‐for‐a‐clinical‐trial/)</a>. </p> </section> </section> <section id="CD007834-sec-0049"> <h3 class="title" id="CD007834-sec-0049">Data collection and analysis</h3> <section id="CD007834-sec-0050"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently used the titles and abstracts of the identified citations to exclude publications that clearly did not meet the inclusion criteria of the review. If either reviewer thought that the publication might possibly meet the criteria, the full paper was obtained for further examination. The same two review authors then reviewed articles that passed this initial screen to determine their fit with the review inclusion criteria. Authorship and results were not blinded. We resolved all types of disagreement by discussion and consensus. A PRISMA flowchart <a href="http://www.prisma-statement.org/PRISMAStatement/FlowDiagram.aspx" target="_blank">(http://www.prisma‐statement.org/PRISMAStatement/FlowDiagram.aspx)</a> was created to detail the inclusion/exclusion process. </p> </section> <section id="CD007834-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>We developed a data extraction form to aid in the collection of relevant data from included studies. As described above in <a href="#CD007834-sec-0037">Criteria for considering studies for this review</a>, we abstracted data on participants, interventions, and outcomes. We also abstracted on to this form the trial characteristics to be used in our assessment of methodological quality. In addition, we collected data on potential effect modifiers, including comorbidities such as end‐stage renal disease, baseline iron status, and pregnancy. Two review authors independently extracted and cross‐checked the data; we handles disagreements by consensus. We contacted study authors to obtain unpublished information when necessary, including outcome data not explicitly stated in the published papers. In cases where data were not presented as means and standard deviations (SDs), we performed additional calculations to allow inclusion in meta‐analyses. Specifically, if only medians and interquartile ranges were provided, we estimated means and SDs as described in <a href="./references#CD007834-bbs2-0069" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;14:135. ">Wan 2014</a>. </p> </section> <section id="CD007834-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors assessed the methodological quality of each trial, using the domain‐based evaluation outlined in the chapter 'Assessing risk of bias in included studies' in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (see sections 8.3‐8.15; <a href="./references#CD007834-bbs2-0052" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Wiley‐Blackwell. ">Higgins 2011</a>). We used the kappa statistic to assess agreement among the review authors regarding quality of the retrieved articles, resolving disagreements by discussion and consensus. In keeping with current <i>Cochrane Handbook</i> guidance (section 8.15), funding by pharmaceutical company was not included in the risk of bias unless there was any suggestion that study design, analysis, or conclusion was influenced by that funding. Information about study funding is included in <a href="./references#CD007834-sec-0099" title="">Characteristics of included studies</a> tables. </p> </section> <section id="CD007834-sec-0053"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed continuous data using mean differences (MDs) where possible, and performed standardised mean difference (SMD) analyses when different measurements were used across studies. SMD was calculated as (SMD = difference in mean outcome between groups/SD of outcome among participants). We calculated risk ratios (RRs) for dichotomous data using the Mantel‐Haenszel method and 95% confidence intervals (CIs). Where possible, we performed intention‐to‐treat analyses to control attrition bias. </p> </section> <section id="CD007834-sec-0054"> <h4 class="title">Unit of analysis issues</h4> <p>We planned to include only the first period of cross‐over trials. In studies in which multiple timepoints of outcome measurement were used, we selected the timepoint that was most similar to timepoints measured in other included studies. </p> </section> <section id="CD007834-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>Missing outcome data from individual studies are discussed in the risk of bias assessments.</p> </section> <section id="CD007834-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>We analysed study heterogeneity using the I<sup>2</sup> statistic. </p> <p>We planned to investigate the following as potential sources of heterogeneity when sufficient data were available. </p> <p> <ol id="CD007834-list-0003"> <li> <p>Different formulations of oral or parenteral iron.</p> </li> <li> <p>Comparator.</p> </li> <li> <p>Duration of treatment.</p> </li> <li> <p>Patient characteristics, including pregnancy or end‐stage renal disease.</p> </li> <li> <p>Baseline levels of ferritin or other documentation of iron deficiency.</p> </li> </ol> </p> </section> <section id="CD007834-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to construct a funnel plot to identify possible publication bias if we identified sufficient numbers of trials (i.e. 10 or more assessing the same outcome). </p> </section> <section id="CD007834-sec-0058"> <h4 class="title">Data synthesis</h4> <p>We generated effect estimates using random‐effects meta‐analyses included in Review Manager version 5.3, which uses the DerSimonian‐Laird meta‐analytic method. </p> <p>We considered risk of bias, inconsistency, indirectness, imprecision, publication bias, magnitude of effect, dose‐response gradient, and influence of plausible residual confounding to generate an assessment of certainty, using the GRADE framework (<a href="./references#CD007834-bbs2-0049" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence ‐ publication bias. Journal of Clinical Epidemiology2011;64:1277‐82. ">Guyatt 2011</a>; tools at <a href="https://gradepro.org/" target="_blank">https://gradepro.org/</a>). Imprecision was assessed by calculating Optimal Information Size (OIS) to evaluate if included sample sizes were sufficiently powered for each outcome included in the Summary of Findings table. </p> </section> <section id="CD007834-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We prespecified subgroup analyses to examine the effects of different types of participants (e.g. pregnant women or people with end‐stage renal disease) and different formulations of iron (oral versus parenteral). </p> </section> <section id="CD007834-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses for high‐ versus low‐quality trials and for parallel group versus cross‐over trial designs, if we identified sufficient numbers of trials.  </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007834-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007834-sec-0061"></div> <section id="CD007834-sec-0062"> <h3 class="title">Description of studies</h3> <section id="CD007834-sec-0063"> <h4 class="title">Results of the search</h4> <p>The searches yielded 1361 potentially relevant articles; 1040 after removal of duplicates (see <a href="#CD007834-fig-0001">Figure 1</a>). Of these, we excluded 1009 after review of title, abstract, or <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> posting because they did not meet the inclusion criteria. We reviewed the full text of 31 studies. Four studies were ongoing or were completed but had released insufficient data to allow inclusion at the time of this review (e.g. unpublished, no data could be obtained); these are included in the <a href="./references#CD007834-sec-0101" title="">Characteristics of ongoing studies</a> section below. Of the 27 remaining studies, 10 met the criteria for inclusion (<a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a>; <a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>; <a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a>; <a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a>; <a href="./references#CD007834-bbs2-0006" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo‐controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a>; <a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>; <a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a>; <a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>; <a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a>), for a total of 428 participants. Nine studies used a placebo comparator and we included them in a quantitative meta‐analysis. We included the study using pramipexole as a comparator only in the qualitative review. </p> <div class="figure" id="CD007834-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007834-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD007834-sec-0064"> <h4 class="title">Included studies</h4> <p>All 10 included studies were randomised, parallel group trials. For a comparison of key differences in study design, see <a href="#CD007834-tbl-0002">Table 1</a>. Nine compared iron to placebo and one compared iron to a dopamine agonist (<a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>). Resless legs syndrome (RLS) was defined using the 1995 International Restless Legs Syndrome Study Group criteria (IRLSSG) in three studies (<a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a>; <a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a>; <a href="./references#CD007834-bbs2-0067" title="WaltersAS . Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Movement Disorders1995;10(5):634‐42. ">Walters 1995</a>), the 2003 IRLSSG criteria in six studies (<a href="./references#CD007834-bbs2-0033" title="AllenRP , PicchiettiD , HeningWA , TrenkwalderC , WaltersAS , MontplaisirJ . Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Medicine2003;4:101‐19. ">Allen 2003</a>; <a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0006" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo‐controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a>; <a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>; <a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>; <a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a>), the Hopkins telephone diagnostic interview for RLS in three studies (<a href="./references#CD007834-bbs2-0051" title="HeningWA , AllenRP , ThannerS , WashburnT , HecklerD , WalterAS , et al. The Johns Hopkins telephone diagnostic interview for the restless legs syndrome: preliminary investigation for validation in a multi‐center patient and control population. Sleep Medicine2003;4(2):137‐41. ">Hening 2003</a>; <a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a>; <a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a>), and by clinical interview by a neurologist in one study (<a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>). In this latter study, 24 of 28 participants met all four diagnostic criteria for RLS using the 1995 criteria. Four studies included only participants with low or low‐normal iron stores, defined as: serum ferritin &lt; 45 ng/mL (<a href="./references#CD007834-bbs2-0006" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo‐controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a>); serum ferritin 15‐50 ng/mL (<a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>); serum ferritin 15‐75 ng/mL (<a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a>); or serum ferritin &lt; 75 ng/mL or the combination of serum ferritin 75‐300 ng/mL and a transferrin saturation &lt; 20% (<a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>). Two studies included only participants on dialysis (haemodialysis or peritoneal dialysis) (<a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a>; <a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a>), while renal disease was an exclusion criterion for most other studies. No study reported inclusion of pregnant women. Three studies administered oral iron as ferrous sulfate 325 mg twice a day (<a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>; <a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>; <a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a>). Seven studies used intravenous iron preparations, three of which were iron sucrose (<a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a>; <a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a>; <a href="./references#CD007834-bbs2-0006" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo‐controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a>), one of which was iron dextran (<a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a>), and three of which were ferric carboxymaltose (<a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a>; <a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>). In all cases, total dosage of intravenous iron was 1000 mg, but this was usually divided into multiple doses. Our primary endpoint of restlessness or unpleasant sensations was evaluated in nine of the included studies, using the IRLS in eight (<a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a>; <a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a>; <a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a>; <a href="./references#CD007834-bbs2-0006" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo‐controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a>; <a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>; <a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>; <a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a>), and a scale developed at the University of Rochester in one (<a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a>). The remaining study (<a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>), the earliest of the included studies, assessed the effect of treatment on sleep and quality of life, but did not explicitly assess restlessness. Four studies were funded by the pharmaceutical companies selling the iron formulations tested in the studies (<a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a>; <a href="./references#CD007834-bbs2-0006" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo‐controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a>; <a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>). </p> <div class="table" id="CD007834-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Key study characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measure of restlessness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IV or oral iron</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of iron</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline iron status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study population</b> </p> <p><b>(if RLS plus another condition)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time of assessment used</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not an inclusion/exclusion criterion</p> <p>(unless &gt; 300 ng/mL); mean ferritin 40.6 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not an inclusion/exclusion criterion</p> <p>(unless &gt; 300 ng/mL); mean ferritin 61.4 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferrous sulfate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded if haemoglobin &lt; 10 g/dL; mean ferritin 117.7 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12‐14 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron sucrose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For inclusion, serum ferritin &lt; 200 ng/mL and transferrin saturation &lt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uremia on haemodialysis at least 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron sucrose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded if haemoglobin &lt; 12 d/dL; mean ferritin 75.2 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0006" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo‐controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron sucrose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For inclusion, serum ferritin &lt; 45 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pramipexole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferrous sulfate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For inclusion, serum ferritin 15‐50 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University of Rochester</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron dextrose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not an inclusion/exclusion criterion; median ferritin 136.3 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End‐stage renal disease</p> <p>on dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For inclusion, serum ferritin &lt; 75 ng/mL or both ferritin 75‐300 ng/mL and transferrin saturation &lt; 20% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferrous sulfate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For inclusion, serum ferritin 15‐75 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IRLS: International Restless Legs Scale<br/> IV: intravenous </p> </div> </div> <p>In the earliest trial (<a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>), 28 participants were randomised to receive either placebo or oral ferrous sulfate liquid, 325 mg twice a day for 16 weeks, at which point participants who wished to continue the study drug as monotherapy were followed for an additional 10 weeks. Iron status and renal function at baseline were not part of the inclusion or exclusion criteria. RLS symptoms were measured with two visual analogue scales, the first which quantified the extent to which RLS symptoms interfered with sleep and the second which quantified how RLS symptoms affected each participant's life, recorded over two weeks at baseline and after 12 weeks. This study was supported by a grant from the National Institutes of Health. </p> <p>In the second trial (<a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a>), 25 participants with end‐stage renal disease on dialysis (22 on haemodialysis, 3 on peritoneal dialysis) were randomised to receive either intravenous iron dextran or placebo. Both interventions were given as a 15 mL test dose (30 mg of iron dextran) over three minutes followed by one hour of observation for adverse reactions; if no adverse reactions were noted, the remaining 485 mL (970 mg of iron dextran) was infused over three hours. RLS symptoms were measured at baseline, one week, two weeks, and four weeks after infusion using the University of Rochester RLS severity scale developed for this study. This three‐question scale assesses frequency of RLS symptoms within the last two days, the amount of distress caused by RLS symptoms, and the duration of symptoms to generate a score from 0 to 10‐point scale (with higher numbers corresponding to increased RLS severity). The funding source for this study was not reported. </p> <p>In the <a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a> trial, 21 participants were randomised to receive either intravenous iron or placebo. A prespecified interim analysis was performed after 18 participants had been enrolled, at which point the study was discontinued because of lack of effect of the intervention, so three of the randomised participants did not complete the protocol. Intravenous iron was given as iron sucrose, 500 mL (containing 500 mg iron sucrose) over 10 hours, followed by a second infusion over 12 hours the following day. The same infusion schedule of saline was given to the placebo group. IRLS scores were measured at baseline and approximately two weeks following the intervention. Other outcome measures included a global rating scale of RLS severity, periodic limb movements during wake and sleep, changes in cerebrospinal fluid ferritin and transferrin levels, objective sleep quality (total sleep time and sleep efficiency during polysomnography), and changes in iron index within the substantia nigra on magnetic resonance imaging (MRI). This study was funded by grants from the National Institutes of Health. </p> <p><a href="./references#CD007834-bbs2-0006" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo‐controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a> randomised 60 participants, all of whom were iron deficient (based on a serum ferritin less than or equal to 45 ng/mL), to receive either intravenous iron or placebo. Iron was delivered as 200 mg of iron sucrose (10 mL of 20 mg/mL Venofer), given five times over a three‐week period. The placebo group received the dosing schedule of 0.9% NaCl. The IRLS scale was measured at baseline, week 3, week 7, week 11, five months, eight months, and 12 months. Serum ferritin and the Epworth Sleepiness Scale (<a href="./references#CD007834-bbs2-0054" title="JohnsMW . A new method for measuring daytime sleepiness: the Epworth sleepiness scale.. Sleep1991;14(6):540‐5. ">Johns 1991</a>) were both measured as well. This study was supported by Renapharma (manufacturer of Venofer). </p> <p><a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a> randomised 18 participants with low or low‐normal ferritin levels (serum ferritin 15‐75 ng/mL) to receive either oral iron (ferrous sulfate 325 mg bid) or matched placebo for 12 weeks. IRLS scores were measured at baseline, six weeks, and 12 weeks after the intervention. Serum ferritin was also measured at 12 weeks, as was a single question regarding change in quality of life compared to prior to beginning the study medication (rated as improved, stayed the same, or worsened). Compliance (based on manual pill count) was measured at six and 12 weeks. The funding source for this study was not reported. </p> <p><a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a> enrolled 46 participants, of whom 43 received all doses of study medication. Participants were randomised to receive either intravenous ferric carboxymaltose or placebo. Iron was delivered as 500 mg of ferric carboxymaltose in 100 mL of normal saline, given on day 0 and day 5. Normal saline was given using the same volume and schedule to participants in the placebo group. Following day 28, participants were assigned to receive ferric carboxymaltose or normal saline based on their serum ferritin and IRLS scores at day 28. Because the treatment assignation at day 28 was not randomised (although it remained blinded), we only considered data gathered before the treatment given on day 28. IRLS scores were measured at baseline, day 14, and day 28. Other outcome measures included the RLS Quality of Life (RLS‐QoL) scale (<a href="./references#CD007834-bbs2-0032" title="AbetzL , VallowSM , KirschJ , AllenRP , WashburnT , EarleyCJ . Validation of the Restless Legs Syndrome Quality of Life questionnaire. Value Health2005;8(2):157‐67. ">Abetz 2005</a>), the Medical Outcomes Study sleep scale (a subjective measure of sleep quality, <a href="./references#CD007834-bbs2-0050" title="HaysRD , StewartAL . Sleep measures. Measuring functioning and well being: the Medical Outcomes Study approach. Durham, NC: Duke University Press, 1992. ">Hays 1992</a>), periodic limb movements (measured via leg actigraphy), the Clinical Global Impression of Change (<a href="./references#CD007834-bbs2-0048" title="GuyW . ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, 1976. ">Guy 1976</a>), a patient global rating of change (the PGI‐C, <a href="./references#CD007834-bbs2-0048" title="GuyW . ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, 1976. ">Guy 1976</a>), and the Fatigue Severity Scale (<a href="./references#CD007834-bbs2-0056" title="KruppLB , LaRoccaNG , Muir‐NashJ , SteinbergAD . The fatigue severity scale. Archives of Neurology1989;46:1121‐3. ">Krupp 1989</a>). This study was supported by Luitpold Pharmaceuticals (manufacturer of ferric carboxymaltose). </p> <p><a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a> randomised 30 participants with low‐normal ferritin levels (15‐50 ng/mL) to either oral iron (ferrous sulfate, 325 mg twice a day) or the dopamine agonist pramipexole (beginning dose 0.25 mg (salt) at bedtime, with titration during the study period based on effect and tolerability). Participants and study personnel were not blinded to treatment allocation. IRLS scores were measured at baseline and at weeks 2, 4, 8, and 12. Serum ferritin, subjective sleep quality, daytime sleepiness, and depressive symptoms were also measured. This study was funded by a grant through the Seoul National University Bundang Hospital. </p> <p><a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a> randomised 64 participants to receive either a single dose of intravenous ferric carboxymaltose (1000 mg in 100 mL normal saline, infused over 15 minutes) or normal saline placebo infused in the same manner. IRLS scores were completed at baseline and at four and six weeks after infusion. Other outcome measures included the Pittsburgh Sleep Quality Index (<a href="./references#CD007834-bbs2-0042" title="BuysseDJ , ReynoldsCF3rd , MonkTH , BermanSR , KupferDJ . The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.. Psychiatry Research1989;28(2):193‐213. ">Buysse 1989</a>), a visual analogue scale of RLS severity, the RLS‐QoL, and the Short Form‐36 Health Survey (SF‐36, <a href="./references#CD007834-bbs2-0070" title="WareJEJr , SherbourneCD . The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Med Care1992;30(6):473‐83. ">Ware 1992</a>). Following collection of data six weeks post‐infusion, participants who received placebo were offered ferric carboxymaltose and all participants were followed in an unblinded fashion through week 30. For these analyses, only data from the initial, randomised, blinded six weeks of the study were included. Grant support for this work was provided by JW Pharmaceutical, and drug support for this work was provided by Vifor Pharma (manufacturer of ferric carboxymaltose). </p> <p><a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a> randomised 110 participants with moderate to severe RLS, who were iron‐deficient but non‐anaemic, to either a single dose of intravenous ferric carboxymaltose (1000 mg) or placebo, infused over 15 +/‐ 2 minutes. IRLS scores were collected at baseline, and weeks 1, 4, 8, and 12. Other collected outcome measures included the Clinical Global Impression of Severity (CGI‐S, <a href="./references#CD007834-bbs2-0048" title="GuyW . ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, 1976. ">Guy 1976</a>), the PGI‐C, the RLS‐6 rating scale (<a href="./references#CD007834-bbs2-0055" title="KohnenR , Stiasny‐KolsterK , OertelWH , BenesH , TrenkwalderC . Severity rating of restless legs syndrome: Validation of the RLS‐6 scale. Sleep2004;27(Suppl 1):A342. ">Kohnen 2004</a>), the RLS‐QoL, the Medical Outcomes Study sleep scale (items assessing satisfaction with sleep and degree of daytime tiredness). This study was supported by Vifor Pharma (manufacturer of ferric carboxymaltose). </p> <p><a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a> randomised 32 participants, all of whom had renal disease on stable haemodialysis treatment for at least 12 months and a diagnosis of RLS. Participants were required to have a baseline serum ferritin &lt; 200 ng/mL and a transferrin saturation &lt; 20%. Participants received either 100 mg of intravenous iron sucrose three days per week for a total of 10 doses, or placebo normal saline of the same volume (50 mL). IRLS was assessed at baseline and two weeks following the final infusion. This study was supported by departmental sources. </p> </section> <section id="CD007834-sec-0065"> <h4 class="title">Excluded studies</h4> <p>We excluded the remaining trials because of one or more of: 1) lack of any control group or use of a different formulation or dose of iron as the control group (<a href="./references#CD007834-bbs2-0012" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless legs syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sang2010;99(4):354‐61. ">Birgegard 2010</a>; <a href="./references#CD007834-bbs2-0013" title="ChoY , KimD , ShinW , EarleyCJ , AllenRP . Lower molecular weight intravenous iron dextran for restless legs syndrome. Sleep2011;34 Suppl 1:A204. ">Cho 2011</a>; <a href="./references#CD007834-bbs2-0014" title="EarleyCJ , HecklerD , AllenRP . The treatment of restless legs syndrome with intravenous iron dextran. Sleep Medicine2004;5:231‐5. ">Earley 2004</a>; <a href="./references#CD007834-bbs2-0015" title="EarleyCJ , HeckerD , AllenRP . Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep Medicine2005;6:301‐5. ">Earley 2005</a>; <a href="./references#CD007834-bbs2-0016" title="EkermoBE , ForsbergP , SchedvinG , BerlinG . An open, randomised, clinical study of oral versus intravenous iron for iron substitution in blood donors. Transfusion2013;53(Suppl 2):36A. ">Ekermo 2013</a>; <a href="./references#CD007834-bbs2-0019" title="MacherS , DrexlerC , StojakovicT , LindenauI , SchrockM , ReinprechtC , et al. Intravenous high‐dose iron supplementation for blood donors with iron deficiency. Haematologica2015;100(Suppl 1):140. ">Macher 2015</a>; <a href="./references#CD007834-bbs2-0020" title="MohriI , Kato‐NishimuraK , TachibanaN , OzonoK , TaniikeM . Restless legs syndrome (RLS): an unrecognized cause for bedtime problems and insomnia in children. Sleep Medicine2008;9:701‐2. ">Mohri 2008</a>; <a href="./references#CD007834-bbs2-0021" title="NCT00895232 . Iron Sucrose In The Treatment of Restless Legs Syndrome: Safety of Three Dose Regimens as Evaluated by Clinical Assessments. clinicaltrials.gov/ct2/show/NCT00895232(first received 5/7/09). ">NCT00895232</a>; <a href="./references#CD007834-bbs2-0022" title="O'KeeffeST , GavinK , LavanJN . Iron status and restless legs syndrome in the elderly. Age and Aging1994;23:200‐3. ">O'Keeffe 1994</a>; <a href="./references#CD007834-bbs2-0023" title="OndoWG . Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Medicine2010;11(5):494‐6. ">Ondo 2010</a>; <a href="./references#CD007834-bbs2-0024" title="SimakajornboonN , GozalD , VlasicV , MackC , SharonD , McGinleyBM . Periodic limb movements in sleep and iron status in children. Sleep2003;26(6):735‐8. ">Simakajornboon 2003</a>; <a href="./references#CD007834-bbs2-0026" title="ZhangX , ChenWW , HuangWJ . Efficacy of the low‐dose Saccharum iron treatment of idiopathic restless legs syndrome. Panminerva Medica2015;57(3):109‐13. ">Zhang 2014</a>; <a href="./references#CD007834-bbs2-0027" title="ZilbermanM , SilverbergDS , SchwartzD , OksenbergA . Restless legs syndrome (RLS) in anemic patients with congestive heart failure and chronic renal failure: lack of effect of anemia treatment. International Journal of Cardiology2010;143(2):205‐7. ">Zilberman 2010</a>), or 2) participant age younger than 18 (<a href="./references#CD007834-bbs2-0018" title="KonofalE , LecendreuxM , DeronJ , MarchandM , CorteseS , ZaimM , et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatric Neurology2008;38:20‐6. ">Konofal 2008</a>; <a href="./references#CD007834-bbs2-0020" title="MohriI , Kato‐NishimuraK , TachibanaN , OzonoK , TaniikeM . Restless legs syndrome (RLS): an unrecognized cause for bedtime problems and insomnia in children. Sleep Medicine2008;9:701‐2. ">Mohri 2008</a>; <a href="./references#CD007834-bbs2-0024" title="SimakajornboonN , GozalD , VlasicV , MackC , SharonD , McGinleyBM . Periodic limb movements in sleep and iron status in children. Sleep2003;26(6):735‐8. ">Simakajornboon 2003</a>), or 3) study performed prior to standard RLS criteria definition in 1995 (<a href="./references#CD007834-bbs2-0022" title="O'KeeffeST , GavinK , LavanJN . Iron status and restless legs syndrome in the elderly. Age and Aging1994;23:200‐3. ">O'Keeffe 1994</a>),or 4) duplicate publication of same trial (<a href="./references#CD007834-bbs2-0017" title="HaltermanMW , SloandJA . An update on the use of intravenous iron for the treatment of restless legs syndrome in end stage renal disease. Salud (i) Ciencia2007;15:860‐5. ">Halterman 2007</a>), 5) absence of original trial data (<a href="./references#CD007834-bbs2-0011" title="AuerbachM . The role of intravenous iron in the treatment of restless legs. American Journal of Hematology2014;89(10):1016. ">Auerbach 2014</a>), or 6) use of a combined iron/folate intervention compared to a control group receiving neither folate nor iron (<a href="./references#CD007834-bbs2-0025" title="VishwakarmaK , KalraJ , GuptaR , SharmaM , SharmaT . A double‐blind, randomized, controlled trial to compare the efficacy and tolerability of fixed doses of ropinirole, bupropion, and iron in treatment of restless legs syndrome (Willis‐Ekbom disease). Annals of Indian Academy of Neurology2016;19(4):472‐7. ">Vishwakarma 2013</a>). </p> </section> </section> <section id="CD007834-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <p>Several of the studies had incomplete reporting, which limited our assessment of potential bias (<a href="#CD007834-fig-0002">Figure 2</a>). The Kappa for agreement between two reviewers about risk of bias was 0.55. We resolved all disagreements by discussion and consensus. </p> <div class="figure" id="CD007834-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007834-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD007834-sec-0067"> <h4 class="title">Allocation</h4> <p>Sequence generation was not clearly described in six of the studies (<a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>; <a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a>; <a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a>; <a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>; <a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a>), and allocation concealment was unclear in three (<a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a>; <a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a>; <a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>). </p> </section> <section id="CD007834-sec-0068"> <h4 class="title">Blinding</h4> <p>Two studies were unblinded by design (<a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a>; <a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>), and one study was reported to be blinded but did not clearly state how the appearance of the intravenous injection was obscured or matched (<a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>). </p> </section> <section id="CD007834-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <p>Incomplete outcome data were a potential problem in three studies (<a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>; <a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>; <a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a>). In the study by Davis et al, six of 14 iron‐treated participants but only one of 14 placebo‐treated participants withdrew before analysis at 14 weeks (the time of primary outcome measurement) and no imputation of missing values was performed. In the Lee study, four of 15 participants in the pramipexole group dropped out due to medication side effects, but no participants dropped out of the iron group for this reason. Sloand et al reported two dropouts in the placebo group but reported outcome data for the entire group, without a clear discussion of how outcome data were imputed for the participants who dropped out. </p> </section> <section id="CD007834-sec-0070"> <h4 class="title">Selective reporting</h4> <p>It is difficult to fully rule out the possibility of selective outcome reporting in any of the trials for which we were unable to find published protocols (<a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a>; <a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>; <a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a>; <a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a>; <a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>; <a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a>; <a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a>). Two additional trials had publicly accessible trial protocols (at <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> and <a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>, respectively; <a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0006" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo‐controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a>), but the date of registration appeared to be after the end date of the trials. </p> </section> <section id="CD007834-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <p>The intervention groups were imbalanced with respect to important potential confounders in one study (<a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a>), with mean baseline RLS severity scores being two points higher (out of a possible 10) in the placebo group and with duration of dialysis being longer in the placebo group (3.3 versus 2.5 years). Both of these could potentially indicate more severe disease in the placebo group, which might be more refractory to therapy. </p> </section> </section> <section id="CD007834-sec-0072"> <h3 class="title" id="CD007834-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD007834-tbl-0001"><b>Summary of findings for the main comparison</b> Iron compared to placebo for the treatment of restless legs syndrome</a> </p> <p>The included studies did not all report the same outcome measures. For our primary outcome measure, subjective restlessness or leg discomfort experienced by the patient, data were available from nine studies. Eight of these studies used the IRLS (<a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a>; <a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a>; <a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a>; <a href="./references#CD007834-bbs2-0006" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo‐controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a>; <a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>; <a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>; <a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a>), and the ninth used a severity scale developed specifically for use in the trial (<a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a>). Several studies measured our primary outcome at multiple time points. For the purpose of comparing changes in restlessness across studies, we attempted to pick a time of assessment that was as consistent as possible across studies. As a result, we analysed changes in scores between two to four weeks after the intervention for intravenous iron, with the two‐week measurement determined by the <a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a> and <a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a> studies, in which this was the only time point available, and the four‐week measurement determined by the <a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a> study, as this was the earliest available time point after the intervention. Time points between two to four weeks were then chosen for the intravenous iron studies of <a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a> (2 weeks), <a href="./references#CD007834-bbs2-0006" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo‐controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a> (3 weeks), <a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a> (23 days after infusion completion), and <a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a> (4 weeks). For oral iron studies, we compared change as measured at 12 weeks, reported in both the <a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a> and <a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a> studies, and as measured from 12 to 14 weeks in the <a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a> study. We considered secondary outcome measures for these same time points, if reported, or for the closest alternate time point when not available. </p> <section id="CD007834-sec-0073"> <h4 class="title">Iron versus placebo</h4> <p>Nine studies compared iron to placebo. Eight of these studies assessed our primary outcome, i.e. severity of restlessness. Of these eight studies, seven could be combined with random effects meta‐analysis of change in IRLS scores from baseline. Iron decreased IRLS severity scores significantly more so than did placebo, with a MD in change in IRLS of ‐3.78 (95% CI ‐6.25 to ‐1.31; I<sup>2</sup> = 66%, 7 studies, 345 participants, <a href="./references#CD007834-fig-0003" title="">Analysis 1.1</a>). Data from the <a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a> study were presented as medians and interquartile ranges for the University of Rochester severity scale, from which we estimated means and standard deviations (SDs), using methodology described by <a href="./references#CD007834-bbs2-0069" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;14:135. ">Wan 2014</a>. For all these eight studies together, the standardised mean difference (SMD) in change in severity was ‐0.74 (95% CI ‐1.26 to ‐0.23; I<sup>2</sup> = 80%, 8 studies, 370 participants, <a href="./references#CD007834-fig-0004" title="">Analysis 1.2</a>) for iron compared to placebo. We rated the certainty regarding these effects of iron versus placebo as moderate (<a href="./full#CD007834-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Considering secondary outcomes, changes in quality of life with treatment were assessed in five studies (<a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a>; <a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>; <a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>; <a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a>). There was no difference in change in quality of life between the treatment and placebo groups in studies using a dichotomised measure of improved versus unchanged or worsened (risk ratio (RR) 2.01, 95% CI 0.54 to 7.45; I<sup>2</sup> = 54%, 2 studies, 39 participants, <a href="./references#CD007834-fig-0010" title="">Analysis 1.8</a>; <a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>; <a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a>), but there was an improvement in quality of life measured as a continuous variable (SMD 0.51, 95% CI 0.15 to 0.87; I<sup>2</sup> = 0%, 3 studies, 128 participants, <a href="./references#CD007834-fig-0011" title="">Analysis 1.9</a>; <a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a>; <a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>). <a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a> also reported significant improvements in several individual quality of life measures contained in the RLS‐QoL. We rated the certainty regarding these effects of iron versus placebo as very low. </p> <p>All nine studies comparing iron to placebo assessed patient satisfaction, either directly or indirectly. In two of the studies, satisfaction was measured directly at a certain time point, when participants were asked if they would prefer to remain in the study or leave the study to start different therapy for RLS (<a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>; <a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a>). In the remaining seven studies, participant dropouts due to lack of efficacy of therapy were reported. Combining these two measures to determine the proportion of participants who chose to leave the study due to lack of efficacy, there was no difference between the iron and placebo groups (RR 0.77, 95% CI 0.41 to 1.47; I<sup>2</sup> = 43%, 9 studies, 391 participants, <a href="./references#CD007834-fig-0012" title="">Analysis 1.10</a>). The <a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>, <a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a>, and <a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a> studies had no dropouts due to lack of efficacy in either group. We rated the certainty regarding these effects of iron versus placebo as low. </p> <p>Patient impression of change using the PGI‐C was reported by two studies. In the <a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a> study, significantly more participants receiving iron rated themselves as much improved or very much improved (45.8% versus 9.5% with placebo, P = 0.03). In the <a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a> study, the PGI‐C was combined with item 2 of the CGI‐I, and significantly more participants receiving iron rated themselves as very much improved and had a CGI of much improved (43.4% versus 14.9%, P = 0.002). </p> <p>Subjective sleep quality was no different between iron and placebo in the studies that reported it (SMD 0.19, 95% CI ‐0.18 to 0.56; I<sup>2</sup> = 9%, 3 studies, 128 participants, <a href="./references#CD007834-fig-0013" title="">Analysis 1.11</a>; <a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a>; <a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>). Objective sleep quality, measured as sleep efficiency during polysomnography, was not significantly different between the iron and placebo groups (‐35.5 +/‐ 92.0 versus ‐41.4 +/‐ 98.2) in the single study that measured it (<a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a>). Periodic limb movements of sleep were measured in two studies (<a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a>), by actigraphy or polysomnography. The decrease after treatment was not significantly different between the iron and placebo groups (SMD ‐0.19, 95% CI ‐0.70 to 0.32; I<sup>2</sup> = 0%, 2 studies, 60 participants, <a href="./references#CD007834-fig-0014" title="">Analysis 1.12</a>). Daytime functioning was assessed in one study using the Epworth Sleepiness Scale, a subjective measure of propensity to fall asleep during routine activities (<a href="./references#CD007834-bbs2-0006" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo‐controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a>). Epworth scores were not given for the treatment groups, but were noted not to be significantly different from placebo at any time point. However, when measured in a single study by the RLS‐6, daytime tiredness was reduced by iron compared to placebo (least squares MD ‐1.5, 95% CI ‐2.5 to ‐0.6; <a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>). Changes in the rate of augmentation were not addressed in any of the included studies. </p> <p>Adverse events were reported for eight of the nine studies comparing iron to placebo. In one study, no adverse events occurred in either group (<a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a>). In five of the studies, data were reported (<a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>; <a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a>; <a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>), or available from the authors (L. Grote, R. Allen) by number of participants in each group to experience any adverse event. In others (<a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a>; <a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a>), adverse events were listed but it was not clear which adverse events were unique occurrences or when an individual participant may have had more than one adverse event. For the purpose of our meta‐analysis, therefore, we included only data from the first six studies. The risk of any adverse event was not different between the iron and placebo groups (RR 1.48, 95% CI 0.97 to 2.25; I<sup>2</sup> = 45%, 6 studies, 298 participants, <a href="./references#CD007834-fig-0015" title="">Analysis 1.13</a>). We rated the certainty regarding these effects of iron versus placebo as moderate. Gastrointestinal side effects (nausea/vomiting, constipation, diarrhoea, and abdominal pain) were considered as unique events (i.e. counted as separate occurrences even if they occurred in the same patient) and were no more common in the iron than placebo groups (1.47, 95% CI 0.77 to 2.80; I<sup>2</sup> = 0%, 8 studies, 380 participants, <a href="./references#CD007834-fig-0016" title="">Analysis 1.14</a>). Participants were no more likely to drop out of the study due to adverse events in the iron than the placebo group (RR 1.91, 95% CI 0.50 to 7.26; I<sup>2</sup> = 0%, 8 studies, 380 participants, <a href="./references#CD007834-fig-0017" title="">Analysis 1.15</a>). No dropouts due to adverse events occurred in five of the studies (<a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a>; <a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a>; <a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a>; <a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a>). We rated the certainty regarding this effect of iron versus placebo as low. </p> <section id="CD007834-sec-0074"> <h5 class="title">Iron versus placebo ‐ subgroup analyses</h5> <p>Subgroup analyses were performed for those studies with participants who were on dialysis versus not on dialysis, those studies selecting for only participants with low or low‐normal baseline iron stores versus studies that did not select for iron deficiency, and for studies administering oral versus intravenous iron. We then further subdivided the intravenous iron studies by performing subgroup analysis on studies administering iron sucrose versus ferric carboxymaltose. </p> <p>Two studies evaluated change in restlessness in participants on dialysis and six studies evaluated this in participants not on dialysis. While the benefit of iron over placebo was apparent for both groups, the benefit was significantly greater in studies of participants on dialysis (Chi<sup>2</sup> = 10.16, P = 0.001, <a href="./references#CD007834-fig-0005" title="">Analysis 1.3</a>). </p> <p>Three studies included only participants selected for low or low‐normal iron stores. There was no significant difference between change in restlessness among those selected for or not selected for iron deficiency at baseline (Chi<sup>2</sup> 1.29, P = 0.26, <a href="./references#CD007834-fig-0006" title="">Analysis 1.4</a>). Three studies additionally reported that baseline ferritin levels were not different between participants whose restlessness responded to iron therapy and those whose did not (<a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0013" title="ChoY , KimD , ShinW , EarleyCJ , AllenRP . Lower molecular weight intravenous iron dextran for restless legs syndrome. Sleep2011;34 Suppl 1:A204. ">Cho 2011</a>; <a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a>). </p> <p>Considering type of iron delivery (oral versus intravenous), there was no significant difference between decrease in restlessness in the single study using oral iron versus the seven studies using intravenous iron (Chi<sup>2</sup> = 1.00, P = 0.32, <a href="./references#CD007834-fig-0007" title="">Analysis 1.5</a>). As a post hoc analysis, we considered iron sucrose (3 studies) versus ferric carboxymaltose (3 studies). There was no significant difference in reduction in restlessness with these two formulations of intravenous iron (Chi² = 0.48, P = 0.49, <a href="./references#CD007834-fig-0008" title="">Analysis 1.6</a>). </p> </section> <section id="CD007834-sec-0075"> <h5 class="title">Iron versus placebo ‐ sources of heterogeneity</h5> <p>There was high heterogeneity for our primary outcome measure of restlessness for the comparison of iron versus placebo (I<sup>2</sup> = 80%). Heterogenity decreased only modestly when considering those studies measuring restlessness with the IRLS (I<sup>2</sup> = 66%). Heterogeneity was considerably lower among studies of participants without renal disease (I<sup>2</sup> = 19%) than those on dialysis (I<sup>2</sup> = 63%). Heterogeneity was somewhat lower when considering only those who were iron deficient at baseline (I<sup>2</sup> = 45%) than those unselected for iron deficiency (I<sup>2</sup> = 86%). Hetereogeneity remained high when considering only studies using intravenous iron (I<sup>2</sup> = 81%), although was very low among those studies using intravenous ferric carboxymaltose (I<sup>2</sup> = 0%). </p> </section> <section id="CD007834-sec-0076"> <h5 class="title">Iron versus placebo ‐ sensitivity analysis</h5> <p>As a sensitivity analysis for quality of trials, we repeated our analysis of restlessness excluding trials with a high risk of bias. This demonstrated a somewhat smaller but still statistically significant benefit of iron over placebo (SMD ‐0.46, 95% CI ‐0.82 to ‐0.10; I<sup>2</sup> = 56%, 7 trials, 338 participants, <a href="./references#CD007834-fig-0009" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD007834-sec-0077"> <h4 class="title">Iron versus dopamine agonist</h4> <p>For the single study comparing iron to a dopamine agonist (<a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>), change in IRLS score from baseline was no different between the iron and pramipexole groups (MD ‐0.40, 95% CI ‐5.93 to 5.13; 1 study, 30 participants). Several secondary outcomes were also not different between treatments, including change in subjective sleep quality, measured by the Pittsburgh Sleep Quality Index and daytime sleepiness measured by the Epworth Sleepiness Scale. Adverse events were reported as being significantly more frequent in the dopamine agonist group, without additional detail provided (<a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>). Four participants in the pramipexole group dropped out due to adverse events, while no participants in the iron group dropped out for this reason. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007834-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007834-sec-0078">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007834-sec-0133">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007834-sec-0078"></div> <section id="CD007834-sec-0079"> <h3 class="title" id="CD007834-sec-0079">Summary of main results</h3> <p>Iron is more effective than placebo at decreasing restlessness and restless legs syndrome (RLS) severity as measured by the International Restless Legs Scale (IRLS). The average improvement in IRLS score above that seen by placebo was 3.78 points, which is above the proposed minimal clinically important change of 2.9 to 3.2 points (<a href="./references#CD007834-bbs2-0036" title="AllenRP . Minimal clinically significant change for the International Restless Legs Syndrome Study Group rating scale in clinical trials is a score of 3. Sleep Medicine2013;14(11):1229. ">Allen 2013b</a>). However, it is lower than the change seen in meta‐analysis of dopamine agonists versus placebo for RLS (4.2 points with ropinirole, 5.2 points with pramipexole, and 7.0 points with rotigotine (<a href="./references#CD007834-bbs2-0060" title="ScholzH , TrenkwalderC , KohnenR , RiemannD , KristonL , HornyakM . Dopamine agonists for restless legs syndrome. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD006009.pub2] ">Scholz 2011</a>)). Assessment of the effect of iron on secondary outcomes was limited by small numbers of studies collecting each secondary outcome, and we rated the certainty level for most secondary outcomes as low or very low. However, available data indicate that iron might be superior to placebo for improving some, but not all, measures of RLS‐related quality of life and are conflicting as to whether iron is superior to placebo in improving daytime sleepiness in participants with RLS. Subjective and objective sleep quality were no more improved by iron than by placebo in included studies. </p> <p>Subgroup analyses indicated that participants on dialysis may be more likely to benefit from iron therapy than participants without renal disease, but there were no significant subgroup effects by baseline iron measures or type of iron administered. However, subgroup analyses are based on relatively small numbers of small studies, e.g. the subgroup of participants included in intravenous iron trials totaled 352, versus only 18 participants with oral iron. Thus, subgroup analyses should be considered exploratory only. </p> <p>Although current practice guidelines recommend replacing iron in people with RLS when serum ferritin levels are &lt; 75 ng/mL (<a href="./references#CD007834-bbs2-0062" title="SilberMH , BeckerPM , EarleyC , Garcia‐BorregueroD , OndoWG . Willis‐Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clinic Proceedings2013;88(9):977‐86. ">Silber 2013</a>), most of the included studies were not limited to participants with serum ferritin values in this range and three studies reported that iron responders and non‐responders did not differ by baseline iron status. Further data are needed to determine the role of baseline iron deficiency in selecting people for RLS treatment with iron. </p> <p>One included study compared iron with an established active treatment (<a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>), i.e. the dopamine agonist pramipexole, rather than to placebo. This study found no difference between iron and pramipexole in reduction of RLS severity. This indirectly supports a clinical benefit of iron for RLS treatment, as dopamine agonists are known to significantly reduce RLS severity compared to placebo. However, the width of the confidence interval (CI) around the mean difference (MD) between these two therapies in the included study was quite wide, such that one of these two treatments may have clinical superiority. </p> <p>Adverse events were no more common with iron therapy than placebo, but may be less common with iron than with a dopamine agonist (as reported by the single study of <a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a>). Although it could not be fully assessed in our review, there may be differences in tolerability between oral and intravenous iron for the treatment of RLS. Tolerability may also be influenced by factors other than route of administration (e.g. formulation of iron). </p> </section> <section id="CD007834-sec-0080"> <h3 class="title" id="CD007834-sec-0080">Overall completeness and applicability of evidence</h3> <p>The total number of participants included in all studies included in this review was relatively low at 428, and half of the included studies had 30 participants or fewer. Secondary outcomes were each included in only a few trials, limiting assessment of these clinically‐important secondary outcomes. Insufficient power and concern about possible publication bias based on the presence of mostly small, often industry‐sponsored trials, resulted in downgrading of confidence levels in results. Larger, well‐designed studies are clearly needed to allow confidence in the estimate of treatment benefit from iron, to understand the effect of iron on secondary outcomes, and to evaluate the role of group differences (e.g. baseline iron status). </p> </section> <section id="CD007834-sec-0081"> <h3 class="title" id="CD007834-sec-0081">Quality of the evidence</h3> <p>Assessment of trial quality was hampered by incomplete reporting of study design, in part likely reflecting evolving guidelines for clinical trial reporting since the earliest included studies were published. Using available data, several studies had potentially high risks of bias, related to high dropout rates without use of last observation carried forward and lack of blinding. Even in studies where dropouts were appropriately handled using intention‐to‐treat with last observation carried forward analyses, high dropout rates may have contributed to a bias toward the null, partially obscuring a true treatment effect (e.g. in <a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>). </p> </section> <section id="CD007834-sec-0082"> <h3 class="title" id="CD007834-sec-0082">Potential biases in the review process</h3> <p>Given the small numbers of participants involved in each trial, this review does not allow for the detection of serious but rare adverse events (e.g. severe infusion reactions with intravenous iron). Because outcomes were not assessed at the same time in each study, we chose to use the time points that were most similar for each route of iron assessment, i.e. two to four weeks for intravenous iron and 12 weeks for oral iron. In several studies (e.g. <a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a>; <a href="./references#CD007834-bbs2-0006" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo‐controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a>; <a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>), there was no significant benefit of iron at the time point we selected for analysis, but a significant benefit was identified at other studied time points; this may have led to an underestimation of a transient or delayed benefit of iron. In other cases (e.g. <a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a>; <a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a>), the time point that we selected for analysis showed a significant benefit, while other reported time points did not, which could have overestimated a benefit of iron. Optimal timing to measure the effect of oral or intravenous iron is not well characterised (<a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a>). </p> </section> <section id="CD007834-sec-0083"> <h3 class="title" id="CD007834-sec-0083">Agreements and disagreements with other studies or reviews</h3> <p>Evidence‐based treatment guidelines for RLS are available from the American Academy of Sleep Medicine (<a href="./references#CD007834-bbs2-0038" title="AuroraRN , KristoDA , BistaSR , RowleyJA , ZakRS , CaseyKR , et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults ‐ an update for 2012: practice parameters with an evidence‐based systematic review and meta‐analysis. Sleep2012;35(8):1039‐62. ">Aurora 2012</a>), the International Restless Legs Syndrome Study Group (specifically addressing long‐term, rather than short‐term, treatment; <a href="./references#CD007834-bbs2-0047" title="Garcia‐BorregueroD , KohnenR , SilberMH , WinkelmanJW , EarleyCJ , HoglB , et al. The long‐term treatment of restless legs syndrome/Willis‐Ekbom disease: evidence‐based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Medicine2013;14:675‐84. ">Garcia‐Borreguero 2013</a>), a combined group of European neurologic and sleep societies (<a href="./references#CD007834-bbs2-0046" title="Garcia‐BorregueroD , Ferini‐StrambiL , KohnenR , O'KeeffeS , TrenkwalderC , HoglB , et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society, and the European Sleep Research Society. European Journal of Neurology2012;19:1385‐96. ">Garcia‐Borreguero 2012</a>), and the American Academy of Neurology (<a href="./references#CD007834-bbs2-0072" title="WinkelmanJW , ArmstrongMJ , AllenRP , ChaudhuriKR , OndoW , TrenkwalderC , et al. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology2016;87(24):2585‐93. ">Winkelman 2016</a>). The American Academy of Sleep Medicine and the International Restless Legs Syndrome Study Group concluded, similar to our initial review (<a href="./references#CD007834-bbs2-0076" title="TrottiLM , BhadrirajuS , BeckerLA . Iron for restless legs syndrome. Cochrane Database of Systematic Reviews2012, Issue 5. [doi: 10.1002/14651858.CD007834.pub2.] ">Trotti 2012</a>), that iron supplementation has not been shown to be effective for RLS (<a href="./references#CD007834-bbs2-0038" title="AuroraRN , KristoDA , BistaSR , RowleyJA , ZakRS , CaseyKR , et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults ‐ an update for 2012: practice parameters with an evidence‐based systematic review and meta‐analysis. Sleep2012;35(8):1039‐62. ">Aurora 2012</a>; <a href="./references#CD007834-bbs2-0047" title="Garcia‐BorregueroD , KohnenR , SilberMH , WinkelmanJW , EarleyCJ , HoglB , et al. The long‐term treatment of restless legs syndrome/Willis‐Ekbom disease: evidence‐based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Medicine2013;14:675‐84. ">Garcia‐Borreguero 2013</a>). In contrast, the European societies considered each iron formulation separately to conclude that intravenous iron sucrose is not effective but that oral ferrous sulfate and intravenous ferric carboxymaltose are probably effective for short‐term treatment (<a href="./references#CD007834-bbs2-0046" title="Garcia‐BorregueroD , Ferini‐StrambiL , KohnenR , O'KeeffeS , TrenkwalderC , HoglB , et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society, and the European Sleep Research Society. European Journal of Neurology2012;19:1385‐96. ">Garcia‐Borreguero 2012</a>). The American Academy of Neurology found moderately strong evidence in support of intravenous ferric carboxymaltose (Level B) and oral ferrous sulfate with vitamin C in those with serum ferritin &lt; 75 ng/mL (Level B) (<a href="./references#CD007834-bbs2-0072" title="WinkelmanJW , ArmstrongMJ , AllenRP , ChaudhuriKR , OndoW , TrenkwalderC , et al. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology2016;87(24):2585‐93. ">Winkelman 2016</a>). A systematic review from the Agency for Healthcare Research and Quality reported moderate evidence for ferric carboxymaltose (<a href="./references#CD007834-bbs2-0071" title="WiltTJ , MacDonaldR , OuelletteJ , KhawajaIS , RutksI , ButlerM , et al. Pharmacologic therapy for primary restless legs syndrome: a systematic review and meta‐analysis. JAMA Internal Medicine2013;173(7):496‐505. ">Wilt 2013</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007834-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007834-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/full#CD007834-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007834-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/full#CD007834-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 1 Change in IRLS severity scale score." data-id="CD007834-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 1 Change in IRLS severity scale score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 2 Change in any measure of restlessness." data-id="CD007834-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 2 Change in any measure of restlessness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 3 Restlessness, Subgroup ‐ renal disease." data-id="CD007834-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 3 Restlessness, Subgroup ‐ renal disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 4 Restlessness, Subgroup ‐ iron status at baseline." data-id="CD007834-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 4 Restlessness, Subgroup ‐ iron status at baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 5 Restlessness, Subgroup ‐ intravenous versus oral iron." data-id="CD007834-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 5 Restlessness, Subgroup ‐ intravenous versus oral iron. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 6 Restlessness, Subgroup ‐ iron sucrose versus ferric carboxymaltose." data-id="CD007834-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 6 Restlessness, Subgroup ‐ iron sucrose versus ferric carboxymaltose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 7 Restlessness, Sensitivity analysis ‐ excluding studies at high risk of bias." data-id="CD007834-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 7 Restlessness, Sensitivity analysis ‐ excluding studies at high risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 8 Quality of life (dichotomous measure)." data-id="CD007834-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 8 Quality of life (dichotomous measure).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 9 Change in quality of life (continuous measure)." data-id="CD007834-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 9 Change in quality of life (continuous measure). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 10 Withdrew to use other RLS medication or because of inadequate RLS symptom control." data-id="CD007834-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 10 Withdrew to use other RLS medication or because of inadequate RLS symptom control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 11 Change in subjective sleep quality." data-id="CD007834-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 11 Change in subjective sleep quality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 12 Change in PLMS." data-id="CD007834-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 12 Change in PLMS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 13 Adverse events." data-id="CD007834-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 13 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 14 Gastrointestinal side effects." data-id="CD007834-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 14 Gastrointestinal side effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron versus placebo, Outcome 15 Drop out due to adverse event." data-id="CD007834-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Iron versus placebo, Outcome 15 Drop out due to adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Iron versus dopamine agonist, Outcome 1 Change in IRLS severity scale score." data-id="CD007834-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Iron versus dopamine agonist, Outcome 1 Change in IRLS severity scale score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007834-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/urn:x-wiley:14651858:media:CD007834:CD007834-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_t/tCD007834-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Iron versus dopamine agonist, Outcome 2 Change in subjective sleep quality." data-id="CD007834-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Iron versus dopamine agonist, Outcome 2 Change in subjective sleep quality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/media/CDSR/CD007834/image_n/nCD007834-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007834-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Iron compared to placebo for the treatment of restless legs syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Iron compared to placebo for the treatment of restless legs syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Patient or population: people with restless legs syndrome</p> <p>Settings: outpatient clinics</p> <p>Intervention: iron</p> <p>Comparison: placebo</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference with iron compared to placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in IRLS severity scale score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>345<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The average reduction in IRLS severity scores in the placebo group ranged from 0.8 points to 12 points </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The reduction in IRLS severity scores was 3.78 points (1.31 to 6.25) lower in the iron group than in the placebo group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in any measure of restlessness</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370<br/> (8 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>The amount of restlessness in the iron group was on average 0.74 SDs (0.23 to 1.26) less than in the placebo group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Quality of life (dichotomous measure)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>39<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>a b c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.01<br/> (0.54 to 7.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>450 per 1000 reported an improvement in quality of life</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>454 more per 1000<br/> (207 fewer to 2903 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in quality of life (continuous measure)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>a b c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>The improvement in quality of life in the iron group was on average 0.51 SDs (0.15 to 0.87) higher than in the placebo group </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrew to use other RLS medication or because of inadequate RLS symptom control</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>391<br/> (9 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>a c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.77<br/> (0.41 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 fewer per 1000<br/> (115 fewer to 92 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>298<br/> (6 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.48<br/> (0.97 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 more per 1000<br/> (8 fewer to 325 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Drop out due to adverse event</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>398<br/> (9 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>a c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.91<br/> (0.50 to 7.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 more per 1000<br/> (8 fewer to 98 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>IRLS</b> : International Restless Legs Scale; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> We downgraded one level for publication bias for several reasons: 1) one study completed in 2012 (<a href="./references#CD007834-bbs2-0029" title="NCT00685815 . Intravenous Iron Metabolism in Restless Legs Syndrome. https://clinicaltrials.gov/ct2/show/NCT00685815 (first submitted 5/23/08). ">NCT00685815</a>) for which published results could not be found in the search; 2) generally small sample sizes; and 3) the majority of participants were in trials funded by pharmaceutical companies.<br/> <sup>b</sup>We downgraded one level for the possibility of selective outcome reporting, as this outcome was infrequently reported across studies.<br/> <sup>c</sup>We downgraded one level because the Optimal Information Size (OIS) calculation suggests insufficient power for this outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Iron compared to placebo for the treatment of restless legs syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/full#CD007834-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007834-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Key study characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measure of restlessness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IV or oral iron</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of iron</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline iron status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study population</b> </p> <p><b>(if RLS plus another condition)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time of assessment used</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0001" title="AllenRP , AdlerCH , DuW , ButcherA , BregmanDB , EarleyCJ . Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi‐centred, placebo‐controlled preliminary clinical trial. Sleep Medicine2011;12(9):906‐13. ">Allen 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not an inclusion/exclusion criterion</p> <p>(unless &gt; 300 ng/mL); mean ferritin 40.6 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0002" title="ChoYW , AllenRP , EarleyCJ . Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine2016;25:16‐23. ">Cho 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not an inclusion/exclusion criterion</p> <p>(unless &gt; 300 ng/mL); mean ferritin 61.4 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0003" title="DavisBJ , RajputA , RajputML , AulEA , EichhornGR . A randomized, double‐blind, placebo‐controlled trial of iron in restless legs syndrome. European Neurology2000;43:70‐5. ">Davis 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferrous sulfate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded if haemoglobin &lt; 10 g/dL; mean ferritin 117.7 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12‐14 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0004" title="DengY , WuJ , JiaQ . Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo‐controlled study. Medical Science Monitor2016;23:1254‐60. ">Deng 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron sucrose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For inclusion, serum ferritin &lt; 200 ng/mL and transferrin saturation &lt; 20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uremia on haemodialysis at least 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0005" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10:206‐11. ">Earley 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron sucrose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded if haemoglobin &lt; 12 d/dL; mean ferritin 75.2 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0006" title="GroteL , LeissnerL , HednerJ , UlfbergJ . A randomized, double‐blind, placebo‐controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron sucrose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For inclusion, serum ferritin &lt; 45 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0007" title="LeeCS , LeeSD , KangSH , ParkHY , YoonIY . Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndromre patients with low serum ferritin. European Journal of Neurology2014;21:260‐6. ">Lee 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pramipexole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferrous sulfate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For inclusion, serum ferritin 15‐50 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0008" title="SloandJA , ShellyMA , FeiginA , BernsteinP , MonkRD . A double‐blind, placebo‐controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American Journal of Kidney Diseases2004;43(4):663‐70. ">Sloand 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University of Rochester</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron dextrose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not an inclusion/exclusion criterion; median ferritin 136.3 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End‐stage renal disease</p> <p>on dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0009" title="TrenkwalderC , WinkelmannJ , OertelW , VirginG , RoubertB , MezzacasaA , FCM‐RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Movement Disorders2017;32(10):1478‐82. ">Trenkwalder 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For inclusion, serum ferritin &lt; 75 ng/mL or both ferritin 75‐300 ng/mL and transferrin saturation &lt; 20% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007834-bbs2-0010" title="WangJ , O'ReillyB , VenkataramanR , MysliwiecV , MysliwiecA . Efficacy of oral iron in patients with restless legs syndrome and a low‐normal ferritin: A randomized, double‐blind, placebo‐controlled study. Sleep Medicine2009;10(9):973‐5. ">Wang 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferrous sulfate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For inclusion, serum ferritin 15‐75 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>IRLS: International Restless Legs Scale<br/> IV: intravenous </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Key study characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/full#CD007834-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007834-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Iron versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in IRLS severity scale score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.78 [‐6.25, ‐1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in any measure of restlessness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐1.26, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 New Subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐1.26, ‐0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Restlessness, Subgroup ‐ renal disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐1.26, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Normal renal function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.57, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Renal disease requiring dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.18 [‐3.31, ‐1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Restlessness, Subgroup ‐ iron status at baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐1.26, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Low or low‐normal baseline iron stores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.81, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Unselected for baseline iron measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.95 [‐1.85, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Restlessness, Subgroup ‐ intravenous versus oral iron <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐1.26, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Oral iron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.29 [‐2.35, ‐0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Intravenous iron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐1.23, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Restlessness, Subgroup ‐ iron sucrose versus ferric carboxymaltose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐1.09, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Iron sucrose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.88 [‐2.48, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Ferric carboxymaltose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.57, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Restlessness, Sensitivity analysis ‐ excluding studies at high risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.82, ‐0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Quality of life (dichotomous measure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.54, 7.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Change in quality of life (continuous measure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.15, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Withdrew to use other RLS medication or because of inadequate RLS symptom control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.41, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Change in subjective sleep quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.18, 0.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Change in PLMS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.70, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.97, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Gastrointestinal side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.76, 2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Drop out due to adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.50, 7.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Iron versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007834-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Iron versus dopamine agonist</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in IRLS severity scale score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐5.93, 5.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in subjective sleep quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐3.89, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Iron versus dopamine agonist</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007834.pub3/references#CD007834-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007834.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007834-note-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007834-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007834-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD007834-note-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD007834-note-0004">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD007834-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD007834-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD007834-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007834-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007834-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007834\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007834\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007834\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007834\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007834\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007834.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007834.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007834.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007834.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007834.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725278863"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007834.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725278867"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007834.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e77566d93936e',t:'MTc0MDcyNTI3OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 